For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 104,885 | |||
| General and administrative | 18,947 | |||
| Total operating expenses | 123,832 | |||
| Loss from operations | -123,832 | |||
| Interest income | 7,447 | |||
| Interest expense | 4,224 | |||
| Change in fair value of embedded derivatives | -460 | |||
| Other expense, net | -266 | |||
| Total other income | 2,497 | |||
| Net loss | -121,335 | |||
| Unrealized gain (loss) on marketable securities | 131 | |||
| Comprehensive loss | -121,204 | |||
| Basic EPS | -2 | |||
| Diluted EPS | -2 | |||
| Basic Average Shares | 60,561,836 | |||
| Diluted Average Shares | 60,561,836 | |||
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)